Protective immunity induced by peptides of AMA1, RON2 and RON4 containing T-and B-cell epitopes via an intranasal route against toxoplasmosis in mice

Tie-E Zhang¹,², Li-Tian Yin³, Run-Hua Li⁴, Hai-Long Wang¹, Xiao-Li Meng¹ and Guo-Rong Yin¹*

Abstract

Background: *Toxoplasma gondii* is a ubiquitous protozoan intracellular parasite, the causative agent of toxoplasmosis, and a worldwide zoonosis. Apical membrane antigen-1 (AMA1) and rhoptry neck protein (RON2, RON4) are involved in the invasion of T. gondii.

Methods: This study chemically synthesized peptides of TgAMA1, TgRON2 and TgRON4 that contained the T- and B-cell epitopes predicted by bioinformatics analysis. We evaluated the systemic response by proliferation, cytokine and antibody measurements as well as the mucosal response by examining the levels of antigen-specific secretory IgA (SIgA) in the nasal, vesical and intestinal washes obtained from mice after nasal immunization with single (AMA1, RON2, RON4) or mixtures of peptides (A1 + R2, A1 + R4, R2 + R4, A1 + R2 + R4). We also assessed the parasite burdens in the liver and brain as well as the survival of mice challenged with a virulent strain.

Results: The results showed that the mice immunized with single or mixed peptides produced effective mucosal and systemic immune responses with a high level of specific antibody responses, a strong lymphoproliferative response and significant levels of gamma interferon (IFN-γ), interleukin-2 (IL-2) and IL-4 production. These mice also elicited partial protection against acute and chronic *T. gondii* infection. Moreover, our study indicated that mixtures of peptides, especially the A1 + R2 mixture, were more powerful and efficient than any other single peptides.

Conclusions: These results demonstrated that intranasal immunisation with peptides of AMA1, RON2 and RON4 containing T- and B-cell epitopes can partly protect mice against toxoplasmosis, and a combination of peptides as a mucosal vaccine strategy is essential for future *Toxoplasma* vaccine development.

Keywords: *Toxoplasma gondii*, AMA1, RON2, RON4, Peptide epitope, Mucosal vaccine

Background

*Toxoplasma gondii* is a significant obligate intracellular protozoan parasite because it infects a wide variety of warm-blooded animals, including humans [1]. Infection in humans can cause severe ocular, neurologic and sometimes systemic disease, especially in immunocompromised and congenitally infected individuals [2-4]. *Toxoplasma gondii* can sometimes be acquired congenitally by a newborn from an infected mother, congenital toxoplasmosis may cause abortion, neonatal death or fetal abnormalities [4,5]. Currently, *T. gondii* control depends primarily on chemotherapy, but the available medicines have many severe side effects. The development of safe and effective vaccines is the best strategy to prevent toxoplasmosis [6,7].

Successful invasion is the first and important step for the parasite to infect the host cells. The invasion process by *T. gondii* involves a moving junction (MJ) formed between the apex of the parasite and the host cell membrane [4], and the MJ structure is used by *T. gondii* to propel itself inside the cell using a gliding motion. Apical membrane antigen-1 (AMA1) plays a central role during...
invasion of *T. gondii* [8-11] as a member of the moving junction complex [12,13]. Rhoptry neck protein 2 (RON2) is present not only at the nascent MJ [13] but also at the progressing MJ, where it co-localizes with other RON partners. Therefore, RON2 is present at the host cell-parasite interface during the complete invasion process [14]. AMA1 uses the RON2 as a receptor, and the AMA1-RON2 interaction is a key for invasion [14,15]. Moreover RON4 participates in MJ formation and is an indispensable component of the MJ complex [12,13,16].

Because MJ components play an essential role in invasion by *T. gondii*, the proteins in the MJ structure may be potential vaccine candidates. AMA1 has been a key malaria vaccine candidate and induces antibodies that inhibit invasion and confer protection in animals [11,14]. In addition, a plasmid that encodes *T. gondii* AMA1 has been shown to generate a strong specific immune response and to provide effective protection against toxoplasmosis in mice [17]. Experimental studies revealed RON2 was a potential *Plasmodium* vaccine candidate [18]. Recent study has shown that a DNA vaccination that expresses RON4 and RON4 protein (RON4S2) induced immune responses, but failed to protect the mice against chronic toxoplasmosis [19]. All the above studies showed that AMA1, RON2 and RON4 might be potential vaccine antigens against toxoplasmosis.

Vaccine needs to include all the components capable of eliciting a protective immune response, notably the T- and B-cell epitopes. Attempts to develop a peptide vaccine that contains T- and B-cell epitopes for *T. gondii* have shown encouraging results [20,21]. Since bioinformatics has played a significant role in the analysis of protein epitopes, structures and functions, we used bioinformatics to predict the T- and B-cell epitopes of *T. gondii* AMA1, RON2 and RON4 in this study.

The natural site of *T. gondii* infection is the mucosal surface of the intestine, and effective protection may require both mucosal and systemic immune responses. The intranasal route acts as an interesting alternative vaccination route and promoted both systemic and mucosal immune responses to an antigen [22-25], which can be used to target pathogens that invade far from the immunization site, such as the intestines [26].

Although host cell invasion has been well described at the ultrastructural and molecular level, the immunogenicity and protective efficacy of AMA1, RON2 and RON4 are still poorly understood. In this study, we predicted and synthesized the peptides of AMA1, RON2 and RON4 containing the T- and B-cell epitopes of *T. gondii*. We also comprehensively evaluated the immune responses and protective efficacy of a single peptide of AMA1 (A1), RON2 (R2) or RON4 (R4), mixtures of two peptides (A1 + R2, A1 + R4 or R2 + R4) and a mixture of three peptides (A1 + R2 + R4) in BALB/c mice via intranasal immunization for the first time.

**Methods**

**Epitopes prediction and peptides synthesis**

The secondary structure and the B cell epitopes of AMA1, RON2 and RON4 of *Toxoplasma gondii* were predicted by the bioinformatics software of the DNAStar Protein system and the Bcepred online prediction tool [27,28].

Based on the results of these methods, we chose the peptides that have good hydrophilicity, satisfactory flexibility, high accessibility and strong antigenicity, but not the α-helix and β-folded sheets, which do not easily interact with antibodies and generally do not act as epitopes. We also predicted the potential B cell epitopes of TgAMA1, TgRON2 and TgRON4 by using the DNA-MAN v6 software [29]. We used the online service SYFPEITHI (http://www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm) to predict the Th cell epitopes of TgAMA1, TgRON2 and TgRON4. Based on the results obtained with these methods, the overlap regions of the predicted results were regarded as the potential T/B combined epitopes of TgAMA1, TgRON2 and TgRON4.

The chemically synthesized peptides listed in Table 1 were obtained from a peptide specialty laboratory (China Peptides Co., Ltd), which purified peptides by HPLC and verified their chemical identity by mass spectrometry. The concentrations of peptide solutions were determined via quantitative amino acid analysis using a Biochrom 20 Amino Acid Analyzer (Pharmacia Biotech). The purity of peptides was >98% in the lyophilized form.

**Toxoplasma gondii** strain

The tachyzoites of the virulent *T. gondii* RH strain were used to challenge mice, and were obtained by the Peking University Health Science Center (Beijing, China). The parasites were maintained and collected from the peritoneal cavity of infected specific-pathogen-free (SPF) BALB/c mice as previously described [24,25].

**Mice and ethics statement**

Female BALB/c mice were purchased from the Institute of Laboratory Animals, Chinese Academy of Medical

| Source of peptide* | Amino acid position | Sequences | Numbers of amino acid | Molecular weight |
|--------------------|---------------------|-----------|-----------------------|-----------------|
| AMA1               | 41-55               | CAEICDPNMPGPHLL | 15 | 1596.84 |
| RON2               | 119-148             | LTAGGPLPHGSWS WSGITTPEVQTGG SQS | 30 | 2993.26 |
| RON4               | 343-374             | KEQFFQFLQHLSA DYPQKQTVYIEL GWW D | 32 | 3891.43 |

*AMA1: Apical membrane antigen-1; RON2: Rhoptry neck protein 2; RON4: Rhoptry neck protein 4.*
immunization and challenge
A total of 176 female BALB/c mice aged 6 weeks were randomly divided into eight groups (22 mice per group). All mice were intranasally immunized with 30 μg AMA1, 30 μg RON2, 30 μg RON4, 15 μg AMA1 plus 15 μg RON2 (A1 + R2), 15 μg AMA1 plus 15 μg RON4 (A1 + R4), 15 μg RON2 plus 15 μg RON4 (R2 + R4) or a mixture of three peptides (10 μg of each peptide, A1 + R2 + R4). The peptides were suspended in 20 μl of sterile PBS, while control mice received 20 μl of sterile PBS alone. Each dose of immunogen was instilled into the nostrils of mice with a micropipettor (10 μl/nostril). All animals were vaccinated three times on days 0, 14 and 21.

Two weeks after the final inoculation (on day 35), 6 mice in each group were anesthetized with sodium pentobarbital (1.5%, 0.1 ml/20 g weight). Blood samples were collected from the mice in each group via retro-orbital plexus puncture, and the sera were stored at -70°C for further analysis. The spleens were collected under aseptic conditions to perform lymphocyte proliferation assays, and the culture supernatants were used for cytokine assays. Mucosal washes, including nasal, vesical and intestinal washes, were collected using PBS and stored at -70°C for secretory IgA (SIgA) assays. In brief, each well of a 96-well microtiter plates was coated overnight at 4°C with 100 μl peptide diluted in 0.05 M carbonate buffer (pH 9.6) at the optimal concentrations of 10 μg/ml for the AMA1, RON2 or RON4 groups, 12 μg/ml for the A1 + R2, A1 + R4 and R2 + R4 groups (6 μg/ml each peptide) or 15 μg/ml for the A1 + R2 + R4 and control groups (5 μg/ml each peptide). Murine sera diluted 1:300 in PBS was applied to the wells, and the plate was incubated at 37°C for 2 h, followed by the addition of goat anti-mouse IgG- or IgA-horseradish peroxidase conjugated antibody as a secondary antibody (Sigma), which was diluted 1:2000 or 1:1000. To analyze the subclasses, the sera were diluted 1:300, applied to the plates and developed with goat anti-mouse IgG1- or IgG2a-horseradish peroxidase conjugated antibody (Proteintech Group, Inc., USA) diluted at 1:2000. The results were expressed as OD492 using an ELISA plate reader and determined in duplicate for each serum sample from at least two independent ELISAs.

spleen cell proliferation assay
Spleen cell proliferation was assayed as previously described [25]. In brief, 5 × 10⁵ cells per well were cultured in triplicate in 96-well plates containing RPMI-1640 medium supplemented with penicillin-streptomycin (1 mM) and 10% fetal calf serum (FCS). The culture was stimulated with either 10 μg/ml of peptide, 5 μg/ml of concanavalin A (Con A) as a positive control or medium alone for proliferation. The plates were incubated in 5% CO₂ at 37°C for 4 days. Next, 10 μl of CCK-8 reagent (Dojindo Laboratories, Japan) was added to each well, and the plate was incubated for 3 h. The optical density was then determined at 450 nm using an ELISA reader. The spleen cell proliferative responses were quantitated using a stimulation index (SI), which was calculated as the ratio of the average OD₄₅₀ of the stimulated cells to the average OD₄₅₀ of the unstimulated cells.

Spleen cell cultures and cytokine assays
Splenocyte suspensions were prepared from six mice in each group 2 weeks after the last immunization, and
1.5 × 10^6 cells/well were cultured in 24-well plates in triplicate in RPMI-1640 containing 10% FCS as described previously [24,25]. The culture was stimulated with 10 μg/ml peptide. The cell-free supernatants were harvested and assayed for interleukin-2 (IL-2) and IL-4 activities at 24 h, while the IL-10 activity was assessed at 72 h and the interferon-gamma (IFN-γ) activity was assessed at 96 h. The concentrations of IL-2, IL-4, IL-10 and IFN-γ were determined by a commercial ELISA kit (PeproTech, USA) according to the instructions provided by the manufacturer. The sensitivity limits of detection of IL-2, IL-4, IL-10 and IFN-γ were 16, 16, 47 and 23 pg/ml, respectively.

**Mucosal washes collection and SlgA determination**

Prior to collecting the samples, the mice were deprived of food for 8 h to deplete the intestinal contents. Nasal washes were collected as described previously [25,31]. Briefly, the trachea was surgically exposed. A micropipette was then passed through the larynx and nasal cavity and a total of 0.6 ml of sterile PBS was flushed five times (0.1 ml per time) per mouse. The intestinal washes were collected using previously described protocols [24,25,32]. The small intestine sample was washed with 3.0 ml PBS. To collect the vesical washes, the bladder was exposed and rinsed gently with sterile PBS using the tip of a micropipette through the urethra. A total of 0.6 ml of sterile PBS was flushed gently in and out of the bladder, and all fluids were collected by micropipette. The bladder was flushed six times (0.1 ml per flush). Every 0.1 ml PBS was re-aspirated into the micropipette and re-injected into the bladder for a total of three cycles before final withdrawal.

All mucosal washes were centrifuged at 1000 × g for 10 min at 4°C to remove any tissue, fecal matter and cellular debris and were stored at -20°C until assayed. The titers of SlgA in the nasal, vesical and intestinal washes were also detected by ELISA at 492 nm as described above.

**Statistical analysis**

The mean of each variable (IgA, total IgG, IgG1, IgG2a, IFN-γ, IL-2, IL-4 and IL-10) was compared between the different groups using one-way ANOVA. All statistical analyses were performed using the SPSS software for Windows version 13.0. The differences were considered statistically significant at P < 0.05. The tachyzoite burdens and survival times for vaccinated and control mice were compared using the Kaplan-Meier method. Levels of significance of the differences between groups were determined by the Student’s unpaired t test. Two-sided P values < 0.05 were considered to indicate statistical significance. Tests of normality for the data within each group were analyzed by the Shopiro-Vilk, P values were > 0.10.

**Results**

**Sera antibodies responses**

Significantly high levels of IgA were detected in the sera from all immunized mice except the RON2 group when compared with the controls (P < 0.05 or P < 0.01). Among the immunized groups, the highest titer was generated in the A1 + R2 group, which was higher than the single peptide groups and A1 + R2 + R4 group (P < 0.05) (Figure 1A). All mice immunized with peptides developed higher total IgG levels, followed in order by the A1 + R2, A1 + R4 and R2 + R4 groups, in comparison to either control group, RON2 group or RON4 group (P < 0.05 or P < 0.01) (Figure 1B). The distributions of serum IgG1 and IgG2a are shown in Figure 2C. With the exception of the levels of IgG2a of mice from the RON2 and RON4 groups, the IgG1 and IgG2a levels of immunized mice were significantly higher than those of the control group (P < 0.05).

**Spleen cell proliferation responses in vitro**

Spleen cells from 8 groups of mice were prepared 2 weeks after the last immunization to assess the proliferative responses to the peptides. As shown in Table 2, the splenocyte stimulation indices (SI) from the immunized groups were higher than that of the PBS group (P < 0.01). A1 + R2 immunization had the strongest activity vs all other groups. In addition, splenocytes from each experimental and control group proliferated well in response to the ConA (data not shown).

**Cytokines production in vitro**

The cell-mediated immunity produced in the immunized mice was evaluated by measuring the amount of cytokines (IFN-γ, IL-2, IL-4 and IL-10) in the supernatants of stimulated splenocyte cultures from mice of all groups. As shown in Table 2, significantly high levels of IFN-γ, IL-2 and IL-4 were detected in mice from all immunized groups compared with the control (P < 0.05). In addition, mice immunized with A1 + R2 had highest levels of IFN-γ, IL-2 and IL-4 than those of the single and mixture peptide groups (P < 0.05). However, the production of IL-10 did not statistically differ among all groups (P > 0.05).

**SlgA production in mucosal washes**

The titers of SlgA in the nasal, vesical and intestinal washes of immunized mice were analyzed two weeks after the last immunization. Significantly higher titers of SlgA were detected in the mucosal washes from all immunized mice compared with the control (P < 0.05 or P < 0.01). As shown in Figure 2A, the mice immunized with peptides cocktail, especially A1 + R2, produced higher levels of SlgA in nasal washes (P < 0.05). Among the three single peptide groups, the highest titer was
Figure 1 Nasal immunization induces antigen-specific IgA and IgG responses in sera. Serum samples were collected and diluted 1:300 to analyze the (A) IgA, (B) total IgG, (C) IgG1 and IgG2a contents by ELISA 14 days after the last immunization. The results are expressed as the means of the OD\textsubscript{492} ± SD (n = 6) and from the two-time determinations. a vs. b, P < 0.05; c vs. d, P < 0.01.

Figure 2 Nasal immunization induces antigen-specific SlgA responses in mucosal washes. Detection of SlgA in (A) nasal, (B) vesical and (C) intestinal washes from immunized mice by ELISA. Washes were obtained from six mice of each group 14 days after the last immunization. The results are expressed as the means of the OD\textsubscript{492} value and standard deviation of the samples. a vs. b, P < 0.05; c vs. d, P < 0.01.
generated in the AMA1 group and the lowest was RON4 group.

The A1 + R2 immunized mice developed the highest levels of SIgA in the vesical washes among all groups. Moreover, the level of SIgA in the vesical washes of mice immunized with the three mixtures (A1 + R2 + R4) was higher than those of the single peptide groups and the R2 + R4 group (P < 0.05) (Figure 2B). As depicted in Figure 2C, the highest levels of SIgA were detected in the intestinal washes of mice immunized with A1 + R2, which were significantly higher than those of the other groups (P < 0.05 or P < 0.01).

**Protection against nonlethal and lethal T. gondii infection**

To evaluate the efficacy of the peptide antigens against *T. gondii* infection, the numbers of tachyzoites in the livers and brains in the mice were determined one month post-infection. As shown in Figure 3, the tachyzoite loads in the liver and brain of all mice immunized with peptides were significantly lower than those in the PBS group (P < 0.05). Furthermore, the lowest tachyzoite loads in liver and brain were observed in the A1 + R2 group (P < 0.01); their reduction rates were 55.79% and 55.68%, respectively, when compared to the PBS group. Additionally, the reduction among the immunized groups did not statistically differ.

The survival rates of the mice were recorded daily following oral challenge for 30 days. The survival curves of all groups of mice are shown in Figure 4. Although the survival rate of all mice immunized with peptides were extended compared to mice from the control group, which died within 13 days, the survival rates of A1 + R2 (70%), AMA1 (60%), A1 + R2 + R4 (50%) and RON2 (40%) immunization reached significant level (P < 0.05).

**Discussion**

Epitope-based vaccines should contain both T- and B-cell epitopes that will serve to induce proper immune responses [33]. In the present study, we focused on the AMA1, RON2 and RON4 involved in the invasion of *Toxoplasma gondii*. We predicted the potential T/B combined epitopes of TgAMA1, TgRON2 and TgRON4 by the bioinformatics method and evaluated the immune responses and protective efficacy of a single peptide or mixtures of peptides by contrast.

As a mucosal pathogen, the natural site of *T. gondii* infection is the mucosal surface where it can replicate efficiently [34]. By taking advantage of the common mucosal immune system (CMIS) [35], mucosal vaccination can elicit immune responses in multiple mucosal effector sites that are far from the immunization site [36]. Therefore, preventing infection at these sites via mucosal active vaccines is a promising and rational approach for vaccine development. Intranasal immunization is an effective and safe way of providing a disseminated mucosal immunity as well as systemic immunity [23,37].

An efficient mucosal vaccine should promote both mucosal and systemic immune responses [35,38]. The mucosal immune system can induce potent protective immunity against harmful pathogens to avoid mucosal colonization and pathogen invasion [39]. Secretory IgA (SIgA) is the main humoral mediator of the mucosal first-line defense system, and it is locally produced in the effector tissues of the mucosal immune system [40]. To evaluate mucosal immune responses, the levels of antigen-specific SIgA in the nasal, vesical and intestinal washes of immunized mice were examined in this study. We found a strong SIgA antibody response in the nasal and vesical washes of mice immunized with peptides. Moreover, the levels of SIgA in washes of mice immunized with mixtures of peptides, especially the A1 + R2 mixture, were significantly enhanced compared to the single peptide immunization. The intestinal IgA system is the best-understood contributor to mucosal immunity. In our study, the strongest SIgA antibody response in

*Table 2* Lymphocyte proliferation and cytokine production by splenocytes stimulated with peptides

| Groups | Lymphocyte SI | Cytokine production (pg/ml) | IL-2 | IL-4 | IL-10 |
|--------|--------------|-----------------------------|------|------|-------|
|        |              | IFN-γ                       |      |      |       |
| PBS    | 0.76 ± 0.04 a| 54.96 ± 12.07 a             | 57.17 ± 8.64 a | 67.17 ± 6.43 a | 84.13 ± 6.43 |
| AMA1   | 2.04 ± 0.12 c| 103.09 ± 18.99 b            | 156.58 ± 12.47 b | 147.75 ± 11.67 b | 102.25 ± 14.67 |
| RON2   | 2.14 ± 0.24 c| 97.39 ± 13.21 b             | 147.33 ± 11.92 b | 136.42 ± 19.22 b | 100.55 ± 19.22 |
| RON4   | 2.21 ± 0.19 c| 94.53 ± 16.60 b             | 134.42 ± 16.30 b | 145.58 ± 12.98 b | 97.75 ± 12.98 |
| A1 + R2| 3.17 ± 0.35 c| 156.62 ± 17.25 c            | 219.71 ± 17.11 c | 190.17 ± 21.11 c | 110.13 ± 11.11 |
| A1 + R4| 2.21 ± 0.31 c| 116.52 ± 16.60 b            | 183.84 ± 14.62 c | 172.08 ± 16.22 b | 111.51 ± 16.22 |
| R2 + R4 | 2.24 ± 0.40 c| 123.36 ± 16.21 b            | 165.75 ± 24.20 b | 174.83 ± 41.98 b | 110.81 ± 11.98 |
| A1 + R2 + R4| 2.54 ± 0.32 c| 108.52 ± 21.21 b            | 162.34 ± 17.11 b | 174.17 ± 21.11 b | 109.75 ± 11.11 |

*ns per group.

*Sp* from mice were harvested 2 weeks after the last immunization. SI represents stimulation index, calculated as the ratio of the OD of stimulated cells to the OD of unstimulated cells. The values for IFN-γ were obtained at 96 h, while the values for IL-2 and IL-4 were obtained at 24 h, and the values for IL-10 were obtained at 72 h. The results are presented as the mean ± SD of three replicate experiments. a vs b: P < 0.05; b vs c: P < 0.05; a vs c: P < 0.01.
the intestinal washes was observed in mice immunized with A1 + R2. Taken together, the above results imply that a mixture of peptides, especially the mixture of two peptides (A1 + R2), was more effective in eliciting a mucosal immune response than a single peptide. Moreover, SIgA antibodies have been shown to reduce *T. gondii* infection of human enterocytes in vitro, which suggests that SIgA secretion is also important in defending against pathogen invasion into the intestinal mucosa [41,42].

System immunity plays a significant role in the defense against pathogens. Consistent with previous reports [42,43], our results showed that mice immunized with peptides had high specific IgG and IgA antibodies in sera. Moreover, the reactions of IgG and IgA of mice immunized with peptide mixtures were significantly enhanced compared to the single peptide immunization. Specific antibodies seem to be important in controlling *T. gondii* infection because the antibodies produced by B cells inhibit the attachment of the parasites to the host cell receptors, and macrophages kill intracellular Ab-coated tachyzoites [44,45]. Additionally, the splenocyte from the peptide immunized mice proliferated more rapidly than those of the control group, and the mice immunized with A1 + R2 showed the strongest increase.

Ideal vaccine candidates should induce both protective cellular Th1 and humoral Th2 responses [46]. The immune regulatory factors IFN-γ, IL-2 and IgG2a are associated with Th1-type responses, and IL-4, IL-10 and IgG1 are associated with Th2-type responses [47,48]. In this study, mice immunized with the peptides exhibited a mixed Th1/Th2 response with high titers of antigen-specific IgG1 and IgG2a antibodies. Our results showed that immunization with mixtures of A1 + R2 peptides can enhance the Th1 or Th2 mediated immunity, as evidenced by high levels of IFN-γ, IL-2 or IL-4 compared with the control group or single peptide groups. However, the production of IL-10 was not statistically different between different groups (P >0.05). Thus IFN-γ-mediated immune responses are necessary to control both the acute and chronic phases of *T. gondii* infection [49,50]. IL-4 may be involved in controlling *T. gondii* tachyzoites in the brain [51].

During the evaluation of protection potency, the highly virulent RH strain of *T. gondii* was used as the challenging infection in this study. All mice immunized with peptides showed significantly protective efficacy against nonlethal *T. gondii* infection compared with the control (P <0.05). Furthermore, the mice immunized with A1 + R2, AMA1, A1 + R2 + R4 and RON2 against lethal *T. gondii* infection showed a significantly higher survival rate (P <0.05); in particular the mice immunized with
A1 + R2 showed the highest reduction of tachyzoite loads in the liver (55.79%) and the brain (55.68%). These results were consistent with previous reports that indicated that a DNA vaccine expressing RON4 and recombinant protein RON4 vaccine failed to protect the mice against oral challenge with *T. gondii* cysts [19].

A growing body of current research has focused on cocktail or multi-antigenic vaccines [18,52]. The enhanced immune responses and protective efficacy induced by mixtures of peptides in this study, especially A1 + R2, coincide with the results of the above-described studies, and the results also indicated that AMA1-RON2 interaction may play a key role in invasion by *Toxoplasma gondii*. This means that the combination of AMA1 and RON2 would be a better solution to fight against *T. gondii* induced immune reaction.

It is worth noting that the enhanced immune responses and protective efficacy induced by mixtures of two peptides, especially AMA1 and RON2 mixture, were more powerful and efficient than the mixture of three peptides. What are the reasons leading to this result? The analysis of the factors showed that the doses of mixture of three peptides group (10 μg each peptide) were less than doses of mixture of two peptides (15 μg each peptide) and it suggests that when antigen dose is too low, even if the three antigens are mixed, a better immune effect is not achieved.

### Conclusions

The intranasal immunization of mice with a single peptide (AMA1, RON2, RON4) or a mixture of peptides (A1 + R2, A1 + R4, R2 + R4 and A1 + R2 + R4) has been shown to induce effective mucosal and systemic immune responses and to elicit partial protection against acute and chronic *T. gondii* infection. Moreover, our study indicated that a mixture of peptides, especially the A1 + R2 mixture, was more powerful and efficient than a single peptide. These results demonstrated that AMA1, RON2 and RON4 containing T- and B-cell epitopes can be considered possible candidate antigens against toxoplasmosis, and a combination of peptides as a mucosal vaccine strategy is essential for future *Toxoplasma* vaccine development.

### Competing interests

The authors declare that they have no competing interests.

### Authors’ contributions

GRY and HLW conceived and designed the study, and GRY critically revised the manuscript; TEZ, LTY, RHL, and XLM performed experiments; TEZ analyzed the data and drafted the first manuscript draft. All authors read and approved the final manuscript.

### Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant No. 81071374) and the Shanxi Provincial Natural Science Foundation (Grant No. 2013011059-4). We thank Liang-Liang Chen, Class S0803, the Second School of Clinical Medicine from Shanxi Medical University, who contributed to animal experiments of this study.

### References

1. Dubey JP, Lindsay DS, Speer CA. Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998;11:267–99.
2. Derouin F, Pelloux H. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14:1089–101.
3. Innes EA. A brief history and overview of *Toxoplasma gondii*. Zoonoses Public Health. 2010;57:1–7.
4. Tenter AM, Heckerth AW, Weiss LM. *Toxoplasma gondii*: from animals to humans. Int J Parasitol. 2000;30:1217–58.
5. Andiappan H, Nisapapong V, Sawangjareon N, Nyunt M, Lau Y, Khaing S, et al. Comparative study on *Toxoplasma* infection between Malaysian and Myanmar pregnant women. Parasites Vectors. 2014;7:564–77.
6. Iljima H, Takahashi I, Kyono H. Mucosal immune network in the gut for the control of infectious diseases. Rev Med Virol. 2001;11:117–33.
7. Jongert E, Roberts CW, Gargano N, Förster-Wald E, Petersen E. Vaccines against *Toxoplasma gondii*: challenges and opportunities. Mem Inst Oswaldo Cruz. 2009;104:252–66.
8. Mittal J, Meissner M, Soldati D, Ward GE. Conditional expression of *Toxoplasma gondii* apical membrane antigen-1 (TgAMA1) demonstrates that TgAMA1 plays a critical role in host cell invasion. Mol Biol Cell. 2005;16:4341–9.
9. Crawford J, Tonkin ML, Grubic O, Boulanger MJ. Structural characterization of apical membrane antigen 1 (AMA1) from *Toxoplasma gondii*. J Biol Chem. 2010;285:15644–52.
10. Santos JM, Ferguson DJ, Blackman MJ, Soldati-Favre D. Intramembrane cleavage of AMA1 triggers Toxoplasma to switch from an invasive to a replicative mode. Science. 2010;331:473–7.
11. Tyler JS, Treeck M, Boothroyd JC. Focus on the ringleader: the role of AMA1 in apicomplexan invasion and replication. Trends Parasitol. 2011;27:410–20.
12. Alexander DT, Mittal J, Ward GE, Bradley P, Boothroyd JC. Identification of the moving junction complex of *Toxoplasma gondii* a collaboration between distinct secretory organelles. PLoS Pathog. 2005;1:e17.
13. Besteiro S, Michelin A, Poncet J, Dubremetz JF, Lebrun M. Export of a *Toxoplasma gondii* rhoptry neck protein complex at the host cell membrane to form the moving junction during invasion. PLoS Pathog. 2009;5:e1000309.
14. Lamanque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, Morlon-Guyot J, et al. The RON2-AMA1 interaction is a critical step in moving junction dependent invasion by apicomplexan parasites. PLoS Pathog. 2011;7:e1001276.
15. Tyler JS, Boothroyd JC. The C-terminus of *Toxoplasma* RON2 provides the crucial link between AMA1 and the host-associated invasion complex. PLoS Pathog. 2011;7:e1001282.
16. Lebrun M, Michelin A, El Haij J, Poncet J, Bradley P, Vali H, et al. The rhoptry neck protein RON4 relocalizes at the moving junction during *Toxoplasma gondii* invasion. Cell Microbiol. 2005;7:1823–33.
17. Dautu G, Munyaka B, Carmen G, Zhang G, Omata Y, Xuenan X, et al. *Toxoplasma gondii*: DNA vaccination with genes encoding antigens MIC2, MSP1, AMA1 and BAG1 and evaluation of their immunogenic potential. Exp Parasitol. 2007;116:273–82.
18. Srinivasan P, Beatty WL, Diouf A, Herrera R, Ambroggio X, Moch JK, et al. Binding of *Plasmodium* merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc Natl Acad Sci U S A. 2011;108:13275–80.
and by immunogenic recombinant protein ROM1 failed to protect mice against chronic toxoplasmal pneumonia. Vaccine. 2011;29:8838–46.
20. Wang Y, Wang M, Wang G, Fang A, Fu B, Yin H, et al. Increased survival time in mice vaccinated with a branched lysine multiple antigenic peptide containing B- and T-cell epitopes from T. gondii antigens. Vaccine. 2011;29:659–69.
21. Zhao G, Zhou A, Lv Q, Meng M, Sun M, Bai Y, et al. Toxoplasma gondii cathepsin proteases are undeveloped prominent vaccine antigens against toxoplasmolysis. BMC Infect. Dis. 2013;13:207.
22. Wu HY, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol. Res. 1997;16:187–201.
23. Wang HL, Pang M, Yin LT, Zhang JH, Meng XL, Yu BF, et al. Intranasal immunization of the recombinant Toxoplasma gondii receptor for activated C kinase 1 partly protects mice against T. gondii invasion. Acta Trop. 2014;137:58–66.
24. Wang HL, Li YQ, Yin LT, Meng XL, Guo M, Zhang JH, et al. Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmolysis. PLoS One. 2013;8:e70884.
25. Yin LT, Hao HW, Wang HL, Zhang JH, Meng XL, Yin GR. Intranasal immunization with recombinant Toxoplasma gondii actin partly protects mice against T. gondii pneumonia. PLoS One. 2013;8:e29765.
26. Igarashi M, Zulpo DL, Cunha IA, Barros LD, Pereira VF, Taroda A, et al. Toxoplasma gondii: humoral and cellular immune response of BALB/c mice vaccinated via intranasal route with rTgROP2. Rev Bras Parasitol Vet. 2010;19:20–6.
27. Yang JM, Wang HL, Du L, Han XM, Ye ZY, Fang Y, et al. Screening and identification of novel B cell epitopes from human heparanase and their anti-invading property for hepatocellular carcinoma. Cancer Immunol. Immunother. 2009;58:1387–96.
28. Zhang ZW, Zhang YG, Wang YL, Pan L, Fang YZ, Jiang ST, et al. Screening and identification of B epitopes from structural proteins of foot-and-mouth disease virus serotype Asia1. Vet Microbiol. 2010;142:53–62.
29. Bai Y, He S, Zhao G, Chen L, Shi N, Zhou H, et al. Intranasal immunization with recombinant Toxoplasma gondii: Bioinformatics analysis, cloning and expression of a novel protein TgILMP1. Exp Parasitol. 2012;132:458–64.
30. Yu H, Huang B, Zhuo X, Chen X, Du A. Evaluation of a real-time PCR assay based on the single-copy SAG1 gene for the detection of Toxoplasma gondii. Vet Parasitol. 2013;197:670–3.
31. Cinney ED, Fernandes S, Hall SJ, Krietz GA, Ulrich RG. Examining the role of nasopharyngeal-associated lymphoreticular tissue (NALT) in mouse responses to vaccines. J Vis Exp. 2012;13:3960.
32. Dinneroni AL, Maciel Jr M, Riggio OR, Piubelli O, de Brito CA, Melo A, et al. Screening and identification of B cell epitopes of structural proteins of foot-and-mouth disease virus serotype Asia1. J Virol. 2007;81:3115–23.
33. Cong H, Gu QM, Yin HE, Wang JW, Zhao QL, Zhou HY, et al. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii. Vaccine. 2008;26:3913–21.
34. Kasper L, Courret N, Darche S, Luangsay S, Minns L, et al. Toxoplasma gondii and mucosal immunity. Int J Parasitol. 2004;34:401–9.
35. Fujikyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, et al. Functional characterization of murine antibodies to Toxoplasma gondii infected cells in the brain. Expert Rev Mol Med. 2011;13:e31.
36. Suzuki Y, Yang Q, Yang S, Nguyen N, Lim S, Lienfeld O, et al. IL-4 is protective against development of Toxoplasma encephalitis. J Immunol. 1996;157:2564–9.
37. Fang R, Feng H, Hu M, Khan MK, Wang L, Zhao J. Evaluation of immune responses induced by SAG1 and MIC3 vaccine cocktails against Toxoplasma gondii. Vet Parasitol. 2012;184:140–6.